Hybrid Antibodies in Cancer Diagnosis and Therapy

Monoclonal Antibodies (Mabs) represent a promising tool for cancer diagnosis and theraphy. Administration of MAbs alone or conjugated to cytotoxic agents has been attempted but has significant limitations. Another potentially effective approach is the use of bispecific or bifunctional antibodies where the capacity to recognize the tumor cell and the toxic agent or lymphocyte activation molecule are united in one MAb. The hybrid molecule can be produced by chemical linkage between the two parentalantibodies, or alternatively by a biological approach that consists in the fusion of the two selected hybridomas. In the resulting quadroma cell the hybridoma immunoglobulin chains recombine randomly to form the bifunctional MAb. In different in vitro and in vivo models, bifunctional MAbs against tumor and CDS at nanomolar concentration has been shown to promote tumor cell killing by cytotoxic T cells. Specific localization of chemotherapeutic drugs in xenografted tumors has been demonstrated in mice pretreated with hybrid MAbs. The advantages of the hybrid MAb approach are that it should reduce the MAb biodistribution problem and that it involves no chemical manipulation between the functional agent and the MAb molecules.

[1]  S. Ménard,et al.  Activation of mononuclear cells to be used for hybrid monoclonal antibody‐induced lysis of human ovarian carcinoma cells , 1988, International journal of cancer.

[2]  S. Ménard,et al.  Human ovarian carcinoma lysis by cytotoxic t cells targeted by bispecific monoclonal antibodies: Analysis of the antibody components , 1988, International journal of cancer.

[3]  G. Jung,et al.  An in-vitro model for tumor immunotherapy with antibody heteroconjugates. , 1988, Immunology today.

[4]  A. Kaubisch,et al.  Human K/natural killer cells targeted with hetero-cross-linked antibodies specifically lyse tumor cells in vitro and prevent tumor growth in vivo. , 1987, Journal of immunology.

[5]  M. Glennie,et al.  Preparation and performance of bispecific F(ab' gamma)2 antibody containing thioether-linked Fab' gamma fragments. , 1987, Journal of immunology.

[6]  A. Lanzavecchia,et al.  The use of hybrid hybridomas to target human cytotoxic T lymphocytes , 1987, European journal of immunology.

[7]  J. Bluestone,et al.  Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody , 1985, Nature.

[8]  Osami Kanagawa,et al.  Hybrid antibodies can target sites for attack by T cells , 1985, Nature.

[9]  D. Stephany,et al.  Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fc gamma receptor antibodies , 1984, The Journal of experimental medicine.

[10]  A. C. Cuello,et al.  Hybrid hybridomas and their use in immunohistochemistry , 1983, Nature.

[11]  V. Raso Antibody Mediated Delivery of Toxic Molecules to Antigen Bearing Target Cells , 1982, Immunological reviews.

[12]  L. Old,et al.  USE OF HYBRID ANTIBODY WITH ANTI-γG AND ANTI-FERRITIN SPECIFICITIES IN LOCATING CELL SURFACE ANTIGENS BY ELECTRON MICROSCOPY , 1968, The Journal of experimental medicine.